BioFactura looks to join the ustekinumab biosimilar race and Cardinal Health provides an interactive tool with state-by-state interchangeable rules.
BioFactura, an Australian company, said it has initiated a phase 1 clinical trial for its ustekinumab biosimilar candidate (BFI-751), referencing Janssen Biotech’s blockbuster product Stelara. Ustekinumab is used for the treatment of Crohn disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis. The drug works by reducing inflammation in the body.
The single-dose, subcutaneous administration clinical trial will assess the effects of the biologic on healthy volunteers in what will be the first in-human trial of the biosimilar candidate. The comparative study will evaluate the pharmacokinetics of BFI-751 with product samples of Stelara available in the US and EU markets.
Safety and tolerability of BFI-751 also will be assessed, along with immune response. Study sites will be in Brisbane and Adelaide, Australia, and Auckland, New Zealand.
Multiple ustekinumab biosimilar candidates are in development, and in the month of July 2021 alone, several biotechnology companies announced trial progress, including Samsung Bioepis, Bio-Thera, and Alvotech. In addition, Dong-A St and Meiji Seika Pharma reported they have agreed on distribution plans for their own ustekinumab candidate (DMB-3115).
Ustekinumab biosimilars are not yet available in the United States or European Union.
Interchangeables
There are no interchangeable biosimilars at the writing of this article, but that could change any minute, given the expectations surrounding the FDA’s ongoing review of an insulin glargine (Semglee) product. This biologic is approved for use but does not have an interchangeable designation, which would allow pharmacists to substitute this biosimilar for the reference product (Lantus) without physician authorization.
However, the FDA’s determination on this and other biosimilars deemed interchangeable would still be subject to state laws that govern the circumstances under which biosimilars may be used interchangeably.
All states have passed interchangeable laws in anticipation of this class of biosimilars, and to make it easy for health care practitioners and pharmacy professionals to understand which rules apply, Cardinal Health, a health care services and products company, has created an interactive US map that allows users to look up interchangeability standards by state.
What is typical of these laws is that physicians must be provided notice of a biosimilar substitution after it happens, and substitutions cannot be made if the physician has expressly indicated on the prescription that the originator product is to be used. These state laws often specify that patients must be notified if they have been given a biosimilar instead of an originator product. The state-by-state laws are spelled out here.
Biosimilars Gastroenterology Roundup: March 2025
April 1st 2025As the biosimilar industry celebrates a decade of growth, the market continues to evolve with expanded treatment options, cost savings, and a flurry of new competitors—yet regulatory challenges, market dynamics, and patient accessibility remain key hurdles to unlocking its full potential.
Will the FTC Be More PBM-Friendly Under a Second Trump Administration?
February 23rd 2025On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy benefit managers (PBMs) with Joe Wisniewski from Turquoise Health, discussing key issues like preferential reimbursement, drug pricing transparency, biosimilars, shifting regulations, and how a second Trump administration could reshape PBM practices.
Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar
March 23rd 2025People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.
Biosimilars Gastroenterology Roundup for November 2024—Podcast Edition
December 1st 2024On this episode of Not So Different, we discuss market changes in the adalimumab space; calls for PBM transparency and biosimilar access reforms grew; new data for biosimilars in gastroenterology conditions; and all the takeaways from this year's Global Biosimilars Week.
Review Calls for Path to Global Harmonization of Biosimilar Development Regulations
March 17th 2025Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.
Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD
March 15th 2025A study evaluating pregnancy outcomes and infant developmental milestones found similar outcomes between pregnant women with inflammatory bowel disease (IBD) who received reference infliximab and those who received a biosimilar.